BR112022011892A2 - Composições farmacêuticas intranasais de inibidores de cgrp - Google Patents
Composições farmacêuticas intranasais de inibidores de cgrpInfo
- Publication number
- BR112022011892A2 BR112022011892A2 BR112022011892A BR112022011892A BR112022011892A2 BR 112022011892 A2 BR112022011892 A2 BR 112022011892A2 BR 112022011892 A BR112022011892 A BR 112022011892A BR 112022011892 A BR112022011892 A BR 112022011892A BR 112022011892 A2 BR112022011892 A2 BR 112022011892A2
- Authority
- BR
- Brazil
- Prior art keywords
- cgrp
- pharmaceutical compositions
- intranasal pharmaceutical
- inhibitors
- intranasal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/006—Sprayers or atomisers specially adapted for therapeutic purposes operated by applying mechanical pressure to the liquid to be sprayed or atomised
- A61M11/007—Syringe-type or piston-type sprayers or atomisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/04—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/08—Inhaling devices inserted into the nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0468—Liquids non-physiological
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Otolaryngology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Mechanical Engineering (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962949351P | 2019-12-17 | 2019-12-17 | |
| PCT/US2020/065452 WO2021127070A1 (en) | 2019-12-17 | 2020-12-17 | Intranasal pharmaceutical compositions of cgrp inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022011892A2 true BR112022011892A2 (pt) | 2022-09-06 |
Family
ID=76478147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022011892A BR112022011892A2 (pt) | 2019-12-17 | 2020-12-17 | Composições farmacêuticas intranasais de inibidores de cgrp |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220401439A1 (https=) |
| EP (1) | EP4076395A4 (https=) |
| JP (1) | JP2023507094A (https=) |
| KR (1) | KR20220114613A (https=) |
| CN (1) | CN114980862A (https=) |
| AU (1) | AU2020408705A1 (https=) |
| BR (1) | BR112022011892A2 (https=) |
| CA (1) | CA3164445A1 (https=) |
| IL (1) | IL293647A (https=) |
| MX (1) | MX2022007336A (https=) |
| WO (1) | WO2021127070A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12521389B2 (en) * | 2019-06-14 | 2026-01-13 | The Regents Of The University Of California | Therapeutic approach to lung disease |
| WO2022109077A1 (en) * | 2020-11-19 | 2022-05-27 | Biohaven Pharmaceutical Holding Company Ltd. | Compositions for improved delivery of cgrp inhibitors |
| JP1706573S (ja) * | 2021-02-15 | 2022-02-01 | 鼻スプレー器 | |
| WO2023064195A1 (en) * | 2021-10-11 | 2023-04-20 | Pfizer Ireland Pharmaceuticals | Cgrp antagonists for treating trigeminal neuralgia |
| CN115429882B (zh) * | 2022-10-19 | 2024-08-06 | 上海交通大学医学院附属第九人民医院 | 伤害性感觉神经细胞调控药物的用途 |
| CA3252054A1 (en) | 2022-11-09 | 2024-05-16 | Tapi Czech Industries S.R.O. | SOLID FORMS OF ZAVÉGÉPANT HYDROCHLORIDE AND THEIR PREPARATION PROCESS |
| CN116003387B (zh) * | 2022-11-20 | 2024-03-26 | 药康众拓(北京)医药科技有限公司 | 一种氘代吲唑丙酰胺类化合物、药物组合物和用途 |
| JP1773931S (ja) * | 2023-05-17 | 2024-06-25 | 鼻スプレー器 | |
| CA225743S (fr) * | 2023-05-17 | 2024-09-12 | Aptar France Sas | Dispositif pour spray nasal |
| CA225744S (fr) * | 2023-05-17 | 2024-09-12 | Aptar France Sas | Dispositif pour spray nasal |
| GB202308123D0 (en) * | 2023-05-31 | 2023-07-12 | Orexo Ab | New copmosition |
| CN120733002B (zh) * | 2025-09-03 | 2025-11-25 | 华中科技大学同济医学院附属同济医院 | Cgrp受体小分子拮抗剂在制备治疗嗜酸性慢性鼻窦炎伴鼻息肉的药品中的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040076587A1 (en) * | 2002-06-19 | 2004-04-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical composition for intranasal administration containing a CGRP antagonist |
| US8481546B2 (en) * | 2010-03-30 | 2013-07-09 | Bristol-Myers Squibb Company | CGRP receptor antagonist |
| US20160199600A1 (en) * | 2013-09-11 | 2016-07-14 | Bixa Research And Health Inc. | Single use intranasal atomizer |
| WO2017001433A1 (en) * | 2015-06-29 | 2017-01-05 | Galderma Research & Development | Cgrp receptor antagonist compounds for topical treatment of skin disorders |
| GB201519194D0 (en) * | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP receptor antagonists |
| KR102444717B1 (ko) * | 2016-04-15 | 2022-09-16 | 하. 룬드벡 아크티에셀스카브 | 인간화 항-pacap 항체 및 그의 용도 |
| CN109476639B (zh) * | 2016-07-22 | 2021-02-26 | 橘生药品工业股份有限公司 | 吡咯烷衍生物 |
| US20190135927A1 (en) * | 2017-09-29 | 2019-05-09 | Bhl Patent Holdings, Llc | Migraine, headache, chronic pain treatment, and prophylaxis options |
| MX2020009856A (es) * | 2018-03-25 | 2020-10-08 | Biohaven Pharm Holding Co Ltd | Rimegepant para trastornos relacionados con el peptido relacionado con el gen para calcitonina (cgrp). |
| AU2020259461A1 (en) * | 2019-04-18 | 2021-11-11 | Allergan Sales, Llc | CGRP antagonists for the treatment of medication overuse headache, post-traumatic headache, post-concussion syndrome and vertigo |
-
2020
- 2020-12-17 CN CN202080086534.4A patent/CN114980862A/zh active Pending
- 2020-12-17 MX MX2022007336A patent/MX2022007336A/es unknown
- 2020-12-17 US US17/769,966 patent/US20220401439A1/en not_active Abandoned
- 2020-12-17 AU AU2020408705A patent/AU2020408705A1/en active Pending
- 2020-12-17 WO PCT/US2020/065452 patent/WO2021127070A1/en not_active Ceased
- 2020-12-17 KR KR1020227024199A patent/KR20220114613A/ko active Pending
- 2020-12-17 JP JP2022535816A patent/JP2023507094A/ja active Pending
- 2020-12-17 BR BR112022011892A patent/BR112022011892A2/pt not_active Application Discontinuation
- 2020-12-17 EP EP20903976.7A patent/EP4076395A4/en not_active Withdrawn
- 2020-12-17 CA CA3164445A patent/CA3164445A1/en active Pending
- 2020-12-17 IL IL293647A patent/IL293647A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021127070A1 (en) | 2021-06-24 |
| US20220401439A1 (en) | 2022-12-22 |
| KR20220114613A (ko) | 2022-08-17 |
| EP4076395A1 (en) | 2022-10-26 |
| CA3164445A1 (en) | 2021-06-24 |
| CN114980862A (zh) | 2022-08-30 |
| EP4076395A4 (en) | 2024-02-07 |
| JP2023507094A (ja) | 2023-02-21 |
| IL293647A (en) | 2022-08-01 |
| MX2022007336A (es) | 2022-09-19 |
| AU2020408705A1 (en) | 2022-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022011892A2 (pt) | Composições farmacêuticas intranasais de inibidores de cgrp | |
| MX2020007853A (es) | Composiciones farmaceuticas para el tratamiento de fibrosis quistica. | |
| NI201700100A (es) | Composiciones farmacéuticas para terapia combinada | |
| MX392313B (es) | Combinaciones de un derivado de 4-pirimidinsulfamida con ingredientes activos para el tratamiento de enfermedades relacionadas con endotelina. | |
| BR112017014067A2 (pt) | composição para tratar doenças relacionadas a il-6 | |
| MX2020005360A (es) | Compuestos y regimen de dosificacion para usarse en la prevencion o tratamiento de enfermedades inflamatorias cronicas y/o autoinmunes. | |
| MX2023014946A (es) | Composicion farmaceutica para administracion oral que comprende derivado de aminopirimidina o su sal. | |
| MX2023006504A (es) | Compuesto de hidroxamato, metodo de preparacion del mismo y aplicacion del mismo. | |
| BR112013021566A2 (pt) | composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula | |
| CO2021015622A2 (es) | Terapias de combinación que comprenden inhibidores de apremilast y tyk2 | |
| CR20220280A (es) | Terapia de combinación que comprende un inhibidor de alk2 y un inhibidor de jak2 | |
| SA521431279B1 (ar) | D1 مشتق تتراهيدرو إيزوكينولين بديل كمعدِّل تفارغي إيجابي | |
| BR112017016817A2 (pt) | derivados heterocíclicos formilados como inibidores de fgfr4 | |
| UY37837A (es) | Nuevos compuestos heterocíclicos como inhibidores de cdk8/19 | |
| BR112017008312A2 (pt) | novos compostos de piridopirimidinona para modular a atividade catalítica de histona lisina demetilases (kdms) | |
| MX2018008903A (es) | COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA. | |
| ECSP22054240A (es) | Compuesto y composici?n como inhibidor de quinasa del receptor pdgf | |
| CO2019002245A2 (es) | Combinación de agonistas de fxr | |
| BR112022007616A2 (pt) | Métodos e composições para tratar doença falciforme com um inibidor de ferroportina (vit-2763) | |
| MX2022003830A (es) | Compuesto de n-(1h-imidazol-2-il)benzamida y composicion farmaceutica que comprende el mismo como ingrediente activo. | |
| PE20220486A1 (es) | Composiciones solidas que comprenden un derivado de egf(a) y una sal de acido n-(8-(2-hidroxibenzoil)amino)caprilico | |
| MX2023001721A (es) | Combinacion de regonafenib e inhibidores de pd-1/pd-l1(2) para el tratamiento contra el cancer. | |
| PH12019500327A1 (en) | Indazole compounds for use in tendon and/or ligament injuries | |
| BR112023022917A2 (pt) | Moduladores de trex1 | |
| BR112022008610A2 (pt) | Composições tópicas compreendendo inibidores de irak4 para uso em tratamento de condições dermatológicas caracterizadas por inflamação |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: PFIZER IRELAND PHARMACEUTICALS (IE) |
|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |